Dr Armin Schwarzbach’s Presentation on Lyme Disease at the LDN 2018 Conference

Dr Schwarzbach concludes with how studies show that Low Dose Naltrexone (LDN) improved immunological symptoms with patients having a good outcome from LDN treatment.  He agrees that studies using Low Dose Naltrexone should be increased as the evidence for LDN’s efficacy and safety is very promising.

Thank you for listening to this presentation.  For more presentations relating to Low Dose Naltrexone for autoimmune disorders please visit www.ldnresearchtrust.org/ldn-conferences